Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2000-03-24
2003-10-28
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S202100
Reexamination Certificate
active
06638514
ABSTRACT:
INTRODUCTION
Dengue fever is caused by any of four serotypes of dengue virus, dengue-1, dengue-2, dengue-3, and dengue-4, which are transmitted to humans by mosquitoes. In adults, dengue infections typically cause self-limited but incapacitating acute illness with fever, muscle pains, headache and an occasional rash. The illness may be complicated by hemorrhagic fever, which may be manifested by a positive tourniquet test, spontaneous petechiae, frank bleeding, and/or shock. Dengue-hemorrhagic fever is fatal in about 0.5% of cases. Patients who have antibody from an earlier dengue infection who are subsequently infected by another dengue strain have been shown to be at higher risk for dengue hemorrhagic fever.
The mosquito vectors of dengue viruses are found in all tropical and sub-tropical areas of the world and in some temperate areas of the United States, Europe, Africa, and the Middle East. In recent years, endemic and epidemic dengue infections have occured in Central and South Ameria, Southeast Asia, India, Africa, the Caribbean and Pacific regions. Vector control is impractical.
An effective vaccine is needed which should confer protection against all four serotypes of dengue.
SUMMARY OF THE INVENTION
The present invention satisfies the need discussed above. The present invention relates to vaccine compositions comprising attenuated dengue virus from all four serotypes. The attenuated virus is provided in an amount sufficient to induce an immune response in a human host, in conjuction with a physiologically acceptable vehicle and may optionally include an adjuvant to enhance the immune response of the host.
Therefore, it is one object of the present invention to provide an attenuated dengue virus composition comprising attenuated more than one dengue virus selected from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4, in any combination.
It is another object of the present invention to provide methods for stimulating the immune system of an individual to induce protection against dengue virus. These methods comprise administering to the individual an immunologically sufficient amount of dengue virus from all four serotypes which have been attenuated by serial passage.
REFERENCES:
Trent, D. W., et al., “Genetic variation and microevolution of dengue 2 virus in Southeast Asia.”, Virology, (1989 Oct.) 172(2): 523-35.*
Rico-Hesse, R., et al., “Molecular evolution of dengue type 2 virus in Thailand.”, American Journal of Tropical Medicine and Hygiene, (1998 Jan.) 58(1):96-101.*
Holmes, E. C. and S. S. Burch, “The causes and consequences of genetic variation in dengue virus.”, Trends in Microbiology, (2000 Feb.) 8(2):74-7.*
Harrison, V. R., et al., “Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates.”, Infection and Immunity, (1977 Oct.) 18(1):151-6.*
Kinney, R. M., et al., “Construction of infectious cDNA clones for dengue 2 virus:strain 16681 and its attenuated vaccine derivative, strain PDK-53.”, Virology, (Apr. 14, 1997) 230(2):300-8.*
PCT International Search Report from international application PCT/US00/08199 (corresponding to 09/535,117), dated Oct. 23, 2000 (9 pages).
Jirakanjanakit et al., “The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine”, Vaccine, GB Butterworth Scientific. Guildford, vol. 17, No. 6, Feb. 1999, pp. 597-601.
Hoke et al., “Preparation of an attenuated Dengue 4 virus vaccine II safety and immunogenicity in humans”, American J. of Tropical Medicine & Hygiene, Lawrence, KS, US, vol. 43, No. 2, Aug. 1990, pp. 219-226.
D. J. Gubler, “The global pandemic of dengue/dengue haemorrhagic fever: Current status and prospects for the future”, Annals Academy of Medicine Singapore, vol. 27, No. 2, Mar. 1998, pp. 227-234.
Putnak et al., “Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice and rhesus monkeys”, J. of Infectious Diseases, vol. 174, No. 6, 1996, pp. 1176-1184.
Puri Beena et al., “Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells”, J. of General Virology, vol. 78, No. 9, 1997, pp. 2287-2291.
Marchette et al., “Preparation of an attenuated dengue 4 virus vaccine I pre-clinical studies”, American J. of Tropical medicine & Hygiene, Lawrence, KS, US, vol. 43, No. 2, Aug. 1990, pp. 212-218.
Bhamarapravati et al., “Live attenuated tetravalent dengue vaccine”, Vaccine, GB Butterworth Scientific Guildford, vol. 18, Mar. 2000, pp. 44-47.
Botstein and Shortle, 1985, “Strategies and applications of in vitro mutagenesis”, Science, vol. 229, No. 4719, pp. 1193-1201.
Clarke and Casals, 1958, “Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses”, Am. J. Trop. Med. Hyg., 7, 561-573.
Halstead et al., 1984, “Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells,” Am J. Trop. Med. Hyg, 33(4), pp. 654-665, 666-671, 672-678, 679-683.
Hayflick, 1988, “History of cell substrates used for human biologicals”, Symposium on Continuous Cell Lines as Substrates for Biologicals, Arlington, Virginia, USA, pp. 11-26.
Hoke et al., 1990, “Preparation of an attenuated Dengue 4 virus vaccine”, Am J. Top. Med. Hyg., 43(2), pp. 219-226.
Marchette, 1990, “Preparation of an attenuated Dengue 4 virus vaccine”, Am J. Top. Med. Hyg., 43(2), pp. 212-218.
Mizrahi, ed., Viral Vaccines, “WHO Attitude to Viral Vaccines”, Wiley-Liss, New York (1990), pp. 39-60.
Putnak et al, 1996, “Development of a purified inactivated, Dengue-2 virus vaccine prototype in vero cells: immunogenecity and protection in mice nad Rhesus monkeys,” J. Infectious Dis., 174, pp.1176-1184.
Russell, et al., “A plaque reduction test for dengue virus neutralizing antibodies”, J. Immunology, vol. 99, No. 2, 1967, pp.285-290.
Scott, 1983, “Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status,” J. Infectious Diseases, vol., 148, No. 6, pp.1055-1060.
Sukhavachana et al, 1966, “Tissue culture techniques for the study of dengue viruses”, Abreges des Communications, Bull. WHO 35, pp. 65-66.
Deller and Smith, 1984, Laboratory Methods, “Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template”, DNA, vol. 3, No. 6, pp.479-488.
Bhamarapravati, 1987, “Immunization with a live attenuated dengue-2-virus candidate vaccine: clinical, immunological and biological responses in adult volunteers”, Bull. WHO, 65(2), pp.189-195.
Conrad et al., “Infection withNippostrongylus Brasiliensisor injection of anti-IgD antibodies markedly enhances Fc-receptor-mediated interleukin 4 production by non-B, non-T cells”, J. Exp. Med., vol. 171, pp.1497-1508.
Dharakul, et al., “Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus Type 2 candidate vaccine”, J. Infect. Dis., vol. 170, pp. 27-33.
Edelman et al., “A live attenuated Dengue-1 vaccine candidate passaged in primary dog kidney cell culture is attenuated and immunogenic for humans”, 1994, Am. J. Trop. Med. Hyg., 170, pp. 1448-1455.
Halstead, 1978, “Studies on the attenuation of Dengue 4”, Asian J. Infectious Dis., vol. 2, pp. 112-117.
Halstead, 1970, “Long ‘cure’ improves results of pig heterograft heart valves”, JAMA, vol. 211, No. 6, pp. 911-916.
Johnson and Roehrig, “New mouse model for Dengue virus vaccien testing”, J. Virology, Jan. 1999, vol. 73, No. 1, pp. 783-786.
Kontny et al., “Gamma interferon augments Fcy receptor-mediated Dengue virus infection of human monocytic cells”, J. Virology, Nov. 1988, vol. 62, No. 11, pp. 3928-3933.
Kurane et al., “Dengue virus-specific human T cell clones”,J. Exp. Med., vol. 170, 1989, pp. 763-775.
Kurane et al., “Activation of T lymphocytes in dengue virus infections”, J. Clin. Invest., vol. 88, 1991, pp. 1473-1480.
Kurane et al., “T cell activation in vivo by Dengue virus infection”, J. Clin. Lab. Immunol., 1995, vol. 46, pp.35-40.
Peters, “Actions of cytokines on the immune r
Dubois Doria R.
Eckels Kenneth H.
Hoke Charles H.
Innis Bruce L.
Kanessa-thasan Niranjan
Arwine Elizabeth
Parkin J. S.
Scheiner Laurie
The United States of America as represented by the Secretary of
LandOfFree
Multivalent dengue virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent dengue virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent dengue virus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3163603